May 20, 2016
By Philip Schneider, MS, FASHP ASBM Advisory Board Chair Having spent 40 years educating students, legislators, patients, and others about medications and pharmacy practice, I’ve learned that the key to changing minds is usually to get people to see things from a new, different angle. For example, as states grapple with how to handle […]
May 12, 2016
On May 10th, ASBM cohosted an educational briefing on biosimilars with the Ohio State University College of Medicine at the University’s Wexner Medical Center in Columbus, OH. The audience was comprised of a broad cross section of stakeholders including patient advocates, physicians, pharmacists, representatives from the Ohio Pharmacy Association, The Ohio Nurses Association, a State Representative, medical […]
May 11, 2016
WASHINGTON, DC—In a letter to the FDA this week, a 70-group coalition of healthcare stakeholders including patient and provider organizations and others urged the use of distinguishable, meaningful suffixes for biosimilars. The letter to Leah Christl, Ph.D., FDA’s associate director for therapeutic biologics, comes on the heels of FDA’s departure from a meaningful to random […]
April 15, 2016
On April 12th, in Geneva, Switzerland, ASBM President Doug Badger and Advisory Board Chair Philip Schneider, MS, FASHP presented to the World Health Organization as part of its 62nd International Nonproprietary Name (INN) Consultation.
April 14, 2016
On April 13th, ASBM Chairman and pediatric rheumatologist Harry L. Gewanter presented to the XIX PANLAR Conference in Panama City, Panama, presented by the Pan American League of Associations for Rheumatology. More than 1000 physicians attended the conference representing countries in Latin America, South America, and the Caribbean. Dr. Gewanter shared data from ASBM’s global […]
April 6, 2016
On April 5th, the FDA approved Inflectra (infliximab-dyyb), making it the second biosimilar approved for sale in the U.S. Notably, Inflectra was approved for all the indications of its reference product for which it applied, including Rheumatoid Arthritis (RA) Ankylosing Spondylitis (AS), and IBD indications such as Ulecerative Colitis (UC) and Crohn’s Disease (CD). Inflectra […]
April 1, 2016
On March 31st, the Alliance for Safe Biologic Medicines (ASBM) gave an educational presentation on biologics and biosimilars for 150 pharmacists attending the 31st annual Seminar by the Sea conference, held by the University of Rhode Island College of Pharmacy.
March 25, 2016
On March 24th, in Louisville, KY, ASBM presented a one hour program entitled “Biosimilars: New Choices, New Challenges”, on the benefits and challenges which will accompany the arrival of biosimilars to the U.S. healthcare landscape.
March 24, 2016
On March 23, ASBM conducted an hour-long presentations entitled “Biosimilars: New Choices, New Challenges” for a group of patients and healthcare providers in St. Louis, MO.
February 16, 2016
On February 15th, ASBM submitted comments to Health Canada on its December 7th Guidance on Subsequent Entry Biologics (the Canadian equivalent of biosimilars), for which Health Canada has sought comment from stakeholders.
